Leerink Partnrs Has Pessimistic View of BBIO FY2026 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Analysts at Leerink Partnrs decreased their FY2026 earnings per share (EPS) estimates for BridgeBio Pharma in a research report issued on Monday, October 27th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($1.14) per share for the year, down from their previous estimate of ($1.11). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Wednesday, October 29th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). The firm had revenue of $108.11 million during the quarter, compared to analyst estimates of $107.71 million. During the same period in the prior year, the business posted ($0.86) EPS. The business’s quarterly revenue was up 4318.0% on a year-over-year basis.

Other equities research analysts have also issued research reports about the stock. Jefferies Financial Group started coverage on shares of BridgeBio Pharma in a research note on Monday, July 14th. They set a “buy” rating and a $70.00 price objective on the stock. HC Wainwright raised their price target on BridgeBio Pharma from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Monday. The Goldman Sachs Group restated a “buy” rating and set a $100.00 price objective on shares of BridgeBio Pharma in a research report on Thursday. Cowen restated a “positive” rating on shares of BridgeBio Pharma in a research report on Thursday. Finally, Oppenheimer boosted their price objective on BridgeBio Pharma from $60.00 to $61.00 and gave the company an “outperform” rating in a research report on Wednesday, August 6th. Twenty analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $73.05.

BridgeBio Pharma Trading Down 4.9%

BBIO stock opened at $63.37 on Thursday. The stock’s 50 day simple moving average is $53.64 and its 200 day simple moving average is $45.34. BridgeBio Pharma has a 12-month low of $21.72 and a 12-month high of $69.48. The firm has a market cap of $12.11 billion, a P/E ratio of -15.16 and a beta of 1.36.

Hedge Funds Weigh In On BridgeBio Pharma

Hedge funds have recently modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of BridgeBio Pharma in the 2nd quarter worth approximately $25,000. First Horizon Corp acquired a new position in shares of BridgeBio Pharma in the 3rd quarter worth approximately $36,000. GAMMA Investing LLC raised its holdings in shares of BridgeBio Pharma by 71.0% in the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock worth $32,000 after buying an additional 382 shares in the last quarter. Jones Financial Companies Lllp acquired a new position in shares of BridgeBio Pharma in the 1st quarter worth approximately $35,000. Finally, Steward Partners Investment Advisory LLC grew its position in BridgeBio Pharma by 22.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock worth $54,000 after acquiring an additional 228 shares during the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at BridgeBio Pharma

In other news, CEO Neil Kumar sold 40,000 shares of the stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $54.78, for a total value of $2,191,200.00. Following the completion of the transaction, the chief executive officer directly owned 855,686 shares of the company’s stock, valued at approximately $46,874,479.08. This represents a 4.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Frank Mccormick sold 1,641 shares of the stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $65.00, for a total value of $106,665.00. Following the completion of the transaction, the director directly owned 878,338 shares of the company’s stock, valued at approximately $57,091,970. The trade was a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 599,554 shares of company stock worth $29,140,892 in the last ninety days. Company insiders own 18.20% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.